These include macrocyclic peptides as allosteric inhibitors, alkene-linked bisubstrate inhibitors that mimic NNMT’s natural substrates, and esterase-sensitive prodrugs of bisubstrate inhibitors for improved cellular uptake and tumor-selective activation. The gene discussed is NNMT; the disease is neoplasm.